Search

Your search keyword '"Ladanyi, M"' showing total 1,051 results

Search Constraints

Start Over You searched for: Author "Ladanyi, M" Remove constraint Author: "Ladanyi, M"
1,051 results on '"Ladanyi, M"'

Search Results

1. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers

2. Local characteristics of the standing genetic diversity of European beech with high within-region differentiation at the eastern part of the range

7. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

9. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

10. P1.21-12 Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation

12. DOK2 inhibits EGFR-mutated lung adenocarcinoma

13. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

15. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

17. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

20. MA13.05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions

27. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

28. Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’: [Annals of Oncology 30 (2019) 1221–1231]

29. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature

30. Immuno-transcriptomic profiling of extracranial pediatric solid malignancies.

31. Sarcoma classification by DNA methylation profiling

34. Oncogenic signaling pathways in the Cancer Genome Atlas

37. The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

38. A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer

40. Cross-Reactivity of EGFR-L858R Mutation-Specific Antibody With HER2 Overexpression in Lung Adenocarcinoma: Report of 2 Index Cases

41. Erratum: The Immune Landscape of Cancer (Immunity (2018) 48(4) (812–830.e14), (S1074761318301213), (10.1016/j.immuni.2018.03.023))

48. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Catalog

Books, media, physical & digital resources